Daiichi Pharmaceutical

Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.

Trade Name	Drug Name	Approved	Patent Expires	Indication
Enhertu	Trastuzumab deruxtecan	2019-12-20		Breast neoplasms , Gastrointestinal neoplasms
Floxin	Ofloxacin	1997-12-16		Corneal ulcer , Prostatitis , Pulmonary tuberculosis , Urinary tract infections , Bacterial infections , Gonorrhea , Bacterial skin diseases , Escherichia coli infections , Soft tissue infections , Chlamydia infections , Helicobacter infections , Bronchitis , Bacterial conjunctivitis , Suppurative otitis media , Staphylococcal infections , Salmonella infections , Proteus infections , Klebsiella infections , Otitis externa , Haemophilus infections , Protozoan infections , Cystitis , Epididymitis
Lixiana	Edoxaban	2015-06-19	2027-2028	Venous thromboembolism , Stroke , Venous thrombosis , Pulmonary embolism
Nilemdo	Bempedoic acid	2020-04-01	2025-2040	Hypercholesterolemia, Dyslipidemias, Atherosclerosis, Hyperlipoproteinemia type ii, Familial combined hyperlipidemia
Nustendi	Bempedoic acid, Ezetimibe	2020-03-27	2025-2040	Hypercholesterolemia, Dyslipidemias, Atherosclerosis, Hyperlipoproteinemia type ii, Familial combined hyperlipidemia
Savaysa	Edoxaban	2015-01-08	2027-2028	Venous thromboembolism, Stroke, Venous thrombosis, Pulmonary embolism
Turalio	Pexidartinib	2019-08-02	2027-2038	Giant cell tumor of tendon sheath
Vanflyta	Quizartinib	2023-07-20	2027-2033	Myeloid leukemia acute, Myeloid leukemia